Acorda Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 31.785 million compared to USD 33.618 million a year ago. Operating loss was USD 15.689 million compared to USD 9.550 million a year ago. Net loss was USD 22.864 million compared to USD 17.421 million a year ago. Basic loss per share from continuing operations was USD 2.29 compared to USD 2.19 a year ago. For the half year, total revenue was USD 60.647 million compared to USD 61.716 million a year ago. Operating loss was USD 44.470 million compared to USD 15.719 million a year ago. Net loss was USD 56.315 million compared to USD 23.893 million a year ago. Basic loss per share from continuing operations was USD 5.79 compared to USD 3 a year ago.